TY - JOUR
T1 - Enhancing antitumor immune responses
T2 - Intracellular peptide delivery and identification of MHC class II-restricted tumor antigens
AU - Wang, Rong Fu
PY - 2002/10
Y1 - 2002/10
N2 - The importance of T-cell-mediated antitumor immunity has been demonstrated in both animal models and human cancer therapy. The identification of major histocompatibility complex (MHC) class I-restricted tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, recent studies suggest that therapeutic strategies that have mainly focused on the use of CD8+ T cells (and MHC class I-restricted tumor antigens) may not be effective in eliminating cancer cells in patients. Novel strategies have been developed for enhancing T-cell responses against cancer by prolonging antigen presentation of dendritic cells to T cells and the inclusion of MHC class II-restricted tumor antigens. identification of MHC class II-restricted tumor antigens, which are capable of stimulating CD4+ T cells, not only aids our understanding of the host immune responses against cancer antigens, but also provides opportunities for developing effective cancer vaccines.
AB - The importance of T-cell-mediated antitumor immunity has been demonstrated in both animal models and human cancer therapy. The identification of major histocompatibility complex (MHC) class I-restricted tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, recent studies suggest that therapeutic strategies that have mainly focused on the use of CD8+ T cells (and MHC class I-restricted tumor antigens) may not be effective in eliminating cancer cells in patients. Novel strategies have been developed for enhancing T-cell responses against cancer by prolonging antigen presentation of dendritic cells to T cells and the inclusion of MHC class II-restricted tumor antigens. identification of MHC class II-restricted tumor antigens, which are capable of stimulating CD4+ T cells, not only aids our understanding of the host immune responses against cancer antigens, but also provides opportunities for developing effective cancer vaccines.
UR - http://www.scopus.com/inward/record.url?scp=0036812676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036812676&partnerID=8YFLogxK
U2 - 10.1034/j.1600-065X.2002.18807.x
DO - 10.1034/j.1600-065X.2002.18807.x
M3 - Article
C2 - 12445282
AN - SCOPUS:0036812676
SN - 0105-2896
VL - 188
SP - 65
EP - 80
JO - Immunological Reviews
JF - Immunological Reviews
ER -